Table 1.
Characteristics of patients in both development and validation cohorts.
| Patient characteristics | Development cohort (n = 160) | Validation cohort (n = 304) | Difference | 95% CI for the difference |
|---|---|---|---|---|
| Gender,n(%) | ||||
| Male | 110 (68.8) | 206 (67.8) | -0.010 | -0.100 to 0.080 |
| Female | 50 (31.3) | 98 (32.2) | ||
| Age, mean ± sd | 65.6 ± 14.0 | 67.2 ± 12.6 | -1.559 | -4.067 to 0.949 |
| CT score, mean ± sd | 19.0 ± 4.9 | 17.6 ± 6.0 | 1.394 | 0.009 to 2.778 |
| Mechanic ventilation, n (%) | 107 (66.9) | 209 (69.0) | -0.021 | -0.111 to 0.069 |
| Comorbidities,n(%) | ||||
| Hypertension | 109 (69.4) | 203 (66.8) | 0.027 | -0.064 to 0.117 |
| Diabetes | 52 (33.1) | 94 (31.0) | 0.021 | -0.069 to 0.111 |
| Obesity | 14 (8.9) | 62 (20.4) | -0.115 | -0.168 to -0.044 |
| HOBP | 8 (5.1) | 13 (4.3) | 0.008 | -0.032 to 0.049 |
| Asthma | 6 (3.8) | 14 (4.6) | -0.008 | -0.047 to 0.032 |
| Coronary disease | 28 (17.8) | 61 (20.1) | -0.022 | -0.099 to 0.054 |
| Cardiomyopathy | 14 (8.9) | 24 (7.9) | 0.010 | -0.043 to 0.063 |
| Total number of patients with comorbidities, n (%) | 120 (75.9) | 235 (77.3) | -0.014 | -0.095 to 0.068 |
| Total number of patients with 2+ comorbidities, n (%) | 72 (45.6) | 137 (45.1) | 0.005 | -0.091 to 0.101 |
| Tocilizumab, n (%) | 38 (23.8) | 51 (16.8) | 0.070 | -0.006 to 0.145 |